Laboratory of Medical Biochemistry, Kobe Pharmaceutical University, Kobe 658‑8558, Japan.
Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima 890‑8544, Japan.
Mol Med Rep. 2022 Nov;26(5). doi: 10.3892/mmr.2022.12856. Epub 2022 Sep 16.
Rubiscolin‑6 is a food‑derived opioid peptide found in that has anti‑nociceptive, memory‑enhancing, anxiolytic‑like and anti‑depressant effects. Rubiscolin‑6 has been reported to have two opposing effects on food intake. Food intake is closely connected to gut motility; however, to the best of our knowledge, the effect of rubiscolin‑6 on gut motility has not been reported. The present study aimed to investigate the effect of rubiscolin‑6 on postprandial motility of the gastric antrum in conscious mice. A catheter was implanted in the gastric antrum of male C57BL/6J mice. Manometric measurements were performed in fasted male mice and chow was then provided to assess motility in the fed state. Rubiscolin‑6, the δ‑opioid receptor antagonist naltrindole, a mixture of rubiscolin‑6 and naltrindole, or vehicle was administered intraperitoneally 30 min after eating. The percentage motor index (%MI) was then calculated. Cumulative food intake was measured in both ‑fed and overnight‑fasted mice. The %MI was significantly lower in mice treated with rubiscolin‑6 compared with that in the other groups, but normalized by treatment with the rubiscolin‑6/naltrindole mixture. The decrease in %MI induced by rubiscolin‑6 remained for 1 h after administration. Cumulative food intake was significantly higher 4 and 6 h after rubiscolin‑6 administration in ‑fed mice but was normalized by the rubiscolin‑6/naltrindole mixture. Food intake 30 min after rubiscolin‑6 administration was normal, but was higher in mice treated with the rubiscolin‑6/naltrindole mixture. Thus, rubiscolin‑6 may have a rapid effect to reduce postprandial antral motility and may subsequently increase food intake after this inhibitory effect disappears. These effects were revealed to be mediated through δ‑opioid receptors. The orexigenic effect of rubiscolin‑6 may be applicable to the treatment of anorexia and cachexia.
Rubiscolin-6 是一种存在于 的食物来源阿片样肽,具有抗伤害感受、增强记忆、类似抗焦虑和抗抑郁作用。Rubiscolin-6 被报道对食物摄入有两种相反的影响。食物摄入与肠道动力密切相关;然而,据我们所知,Rubiscolin-6 对肠道动力的影响尚未报道。本研究旨在探讨 Rubiscolin-6 对清醒小鼠胃窦餐后运动的影响。在雄性 C57BL/6J 小鼠的胃窦中植入导管。在禁食雄性小鼠中进行测压测量,然后给予食物以评估进食状态下的运动。Rubiscolin-6、δ-阿片受体拮抗剂纳曲吲哚、Rubiscolin-6 和纳曲吲哚混合物或载体在进食后 30 分钟内腹膜内给药。然后计算运动指数百分比(%MI)。在进食和过夜禁食的小鼠中测量累积食物摄入量。与其他组相比,Rubiscolin-6 处理的小鼠的 %MI 显着降低,但用 Rubiscolin-6/纳曲吲哚混合物处理后可恢复正常。Rubiscolin-6 诱导的 %MI 降低在给药后 1 小时内持续存在。在进食的小鼠中,Rubiscolin-6 给药后 4 和 6 小时累积食物摄入量显着增加,但用 Rubiscolin-6/纳曲吲哚混合物处理后可恢复正常。Rubiscolin-6 给药后 30 分钟的食物摄入量正常,但用 Rubiscolin-6/纳曲吲哚混合物处理的小鼠食物摄入量更高。因此,Rubiscolin-6 可能具有快速作用,可降低餐后胃窦运动,并在这种抑制作用消失后随后增加食物摄入量。这些作用被证明是通过 δ-阿片受体介导的。Rubiscolin-6 的食欲促进作用可能适用于厌食症和恶病质的治疗。